Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · IEX Real-Time Price · USD
25.24
-1.65 (-6.14%)
At close: Apr 12, 2024, 4:00 PM
25.73
+0.49 (1.94%)
After-hours: Apr 12, 2024, 4:44 PM EDT
-6.14%
Market Cap 703.26M
Revenue (ttm) n/a
Net Income (ttm) -75.52M
Shares Out 27.86M
EPS (ttm) -2.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,782
Open 26.64
Previous Close 26.89
Day's Range 24.44 - 27.25
52-Week Range 9.41 - 32.42
Beta 1.23
Analysts Strong Buy
Price Target 50.00 (+98.1%)
Earnings Date May 13, 2024

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 51
Stock Exchange NASDAQ
Ticker Symbol AVTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for AVTE stock is "Strong Buy." The 12-month stock price forecast is $50.0, which is an increase of 98.10% from the latest price.

Price Target
$50.0
(98.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...

18 days ago - GlobeNewsWire

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

20 days ago - GlobeNewsWire

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...

5 weeks ago - GlobeNewsWire

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerov...

5 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

5 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

8 months ago - GlobeNewsWire

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

9 months ago - GlobeNewsWire

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

11 months ago - GlobeNewsWire

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing

11 months ago - GlobeNewsWire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

11 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 year ago - GlobeNewsWire

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants Phase 1 results showed that AV-101 ...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022

Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor Adaptive and efficient trial design may allow for expedited development timeline whi...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter 2022 Financial Results

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

AV-101 is being developed to address cellular hyperproliferation and resistance to apoptosis in the pulmonary vasculature, which are key features of the pathophysiology of PAH

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces First Quarter 2022 Financial Results

WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) --  Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the liv...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Initiation of IMPAHCT Phase 2b/Phase 3 Trial of AV-101 In Pulmonary Arterial Hypertension

WALTHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter 2021 Financial Results

WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index

WALTHAM, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter 2021 Financial Results

WALTHAM, Mass. , Aug. 16, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc.   (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the li...

2 years ago - GlobeNewsWire

Aerovate Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters' Option to Purchase Additional Shares

BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of pati...

3 years ago - GlobeNewsWire